UCB SA - BNP Paribas Fortis

Profit from continuing operations
Profit from discontinuing operations
Net profit (after minority interests)
Recurring EBITDA
Adjusted net profit 2
Capital expenditures (including intangible assets)
Net financial debt
Cash flow operating activities
Number of shares non-diluted
EPS (€ per non-diluted share)
Adjusted EPS (€ per non-diluted share)
A11250830/2.25/23 Oct 2009 52
515
1
516
363
135
34
2 166
( 45)
180
2.86
0.75
107
1
108
358
143
73
2 443
185
180
0.59
0.79
1 Except for the net financial debt, where 2008 relates to the situation as published in the audited consolidated financial statements as
at 31 December 2008.
2 Adjusted for after- tax impact of one-off items and after-tax contribution from discontinued operations.
4. CURRENT ORGANISATIONAL STRUCTURE
UCB is the holding company of the UCB Group, with over 130 subsidiaries, the large majority of which
are directly or indirectly wholly owned. A complete list of the subsidiaries of the UCB Group is
incorporated at Part X, “Associated Companies and Shareholdings”.
The current structure of the UCB Group has evolved through the implementation of the SHAPE
programme in late 2008 and 2009 which has streamlined management and focused investment across
the UCB Group. A particular emphasis of the SHAPE programme has been to establish partnerships or
joint ventures in core disease areas, in addition to which the Issuer is also increasingly using
partnerships with outsourcing providers to perform a range of activities. These include activities along
the value chain, ranging from strategic research work in UCB NewMedicines and the processing of
non-serious cases in the pharmacovigilance function to transactional activities in support functions such
as finance. This allows the Issuer to access skills beyond its current capacities, and the Issuer believes
that it benefits from efficiencies in cost savings and process improvements throughout the organisation.
(a) UCB NewMedicines
UCB NewMedicines is responsible for new drug generation for the Issuer, comprising research,
formulation and non-clinical departments. UCB NewMedicines has an increased emphasis on
external collaboration and research in order to sustain pipeline innovation. UCB NewMedicines
employs a collaborative external approach to access cutting-edge knowledge and ideas, carefully
selecting appropriate discovery research and early stage clinical partnerships and collaborations to
enrich its activities and seeking partners from multiple sources, both in industry and in academia. The
use of ‘incubators’ enables external experts to complement and strengthen the science within UCB
NewMedicines as well as allowing non-core inventions to be taken forwards outside the organisation.
Outsourcing and increased virtual working is also bringing in external expertise while allowing a
sharper focus for internal resources.
A4 – 7.1